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IFN-α has been used for decades to treat chronic hepatitis B and C, and as an off-label treatment 
for some cases of hepatitis E virus (HEV) infection. TNF-α is another important cytokine involved in 
inflammatory disease, which can interact with interferon signaling. Because interferon-stimulated 
genes (ISGs) are the ultimate antiviral effectors of the interferon signaling, this study aimed to 
understand the regulation of ISG transcription and the antiviral activity by IFN-α and TNF-α. In 
this study, treatment of TNF-α inhibited replication of HCV by 71 ± 2.4% and HEV by 41 ± 4.9%. 
Interestingly, TNF-α induced the expression of a panel of antiviral ISGs (2-11 fold). Blocking the 
TNF-α signaling by Humira abrogated ISG induction and its antiviral activity. Chip-seq data analysis 
and mutagenesis assay further revealed that the NF-κB protein complex, a key downstream element 
of TNF-α signaling, directly binds to the ISRE motif in the ISG promoters and thereby drives their 
transcription. This process is independent of interferons and JAK-STAT cascade. Importantly, when 
combined with IFN-α, TNF-α works cooperatively on ISG induction, explaining their additive antiviral 
effects. Thus, our study reveals a novel mechanism of convergent transcription of ISGs by TNF-α and 
IFN-α, which augments their antiviral activity against HCV and HEV.
Cytokines orchestrate cellular communication in an autocrine, juxtacrine, or paracrine fashion through binding 
to distinct families of receptors, triggering specific immune responses against invading pathogens. The interferon 
(IFN)-mediated innate immune response is probably the most prominent response and provides a robust first 
defense line. Among different types of interferons, IFN-α (a type I member) has been used for decades to treat 
chronic hepatitis B or C infection in the clinic1. When stimulated by its cognate ligand, interferon receptors 
respond by the activation of kinases of the Janus family (JAKs), which in turn phosphorylate tyrosine residues in 
the intracellular tail of the interferon receptors. These phosphotyrosines serve as docking sites for recruitment 
and phosphorylation of the Signal Transducers and Activators of Transcription (STAT) family, which provokes 
STAT1 and STAT2 dimerization and subsequent binding to interferon regulatory factor 9 (IRF9) to form the 
IFN-stimulated gene factor 3 (ISGF3) complex. The ISGF3 complex translocates into the nucleus, and binds 
to specific promotor elements denoted as interferon signaling response elements (ISREs) and thus mediate the 
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transcription of so-called interferon-stimulated genes (ISGs). ISGs are the ultimate antiviral effectors of the inter-
feron signaling.
It is generally believed that ISGs are predominantly induced by interferons. However, ISGs are still 
up-regulated in embryonic fibroblasts from IFN alpha/beta receptor knockout mouse upon infection of West 
Nile virus2. These observations suggest the existence of alternative mechanisms of regulating ISG transcription. 
But these non-canonical mechanisms remain largely unknown.
Tumor necrosis factor alpha (TNF-α is another important cytokine that mediates host response to infections. 
TNF-α /TNFR interactions can play decisive roles in the outcome of a number of viral infections, contributing to 
virus control or immune mediated pathology3. Deregulation of TNF-α is associated with many pathological con-
ditions, including various types of arthritis and inflammatory bowel disease (IBD)4. TNF-α inhibitors have been 
successfully used in the clinic to treat these chronic immune-mediated diseases5. However, patients receiving 
TNF-α inhibitors are often at high risk of viral infections6. Treatment with TNF-α inhibitors have been reported 
to increase reactivation of concurrent chronic hepatitis B and potentially increase hepatitis C virus (HCV) rep-
lication7, further supporting the importance of TNF-α in defending the human body against viral infections. 
Interestingly, several previous studies reported crosstalk between TNF-α and the antiviral interferon signaling 
and ISG expression in the setting of vesicular stomatitis virus8, hepatitis C virus (HCV)9, respiratory virus10 and 
poxvirus infections11.
However, the exact antiviral mechanisms of TNF-α and how it cooperates with the interferon signaling remain 
largely elusive, thus prompting us to explore their molecular basis. Here we report that TNF-α alone was sufficient 
to induce the expression of ISGs and to exert antiviral activity against HCV and hepatitis E virus (HEV). This is 
through the activation of the NF-κ B signaling but independent of the canonical interferon pathway. Surprisingly, 
we found a consensus DNA binding sequence between the NF-κ B and ISRE motif with bioinformatics analysis. 
Functional assays revealed that the NF-κ B complex is able to bind to the ISRE motif and directly activates the 
transcription of antiviral ISGs. Combination of TNF-α with IFN-α further boosts the induction of ISGs and 
results in augmented antiviral activity against HCV and HEV. Thus, this study identified a non-canonical mecha-
nism of driving antiviral ISG transcription, which provides the molecular basis for the antiviral action of TNF-α 
and its additive antiviral effect with interferon.
Results
TNF-α activates ISG transcription and exerts antiviral activity against HCV and HEV. TNF-α 
is involved in host responses to a variety of pathogen invasions, including HCV and HEV infections9,12. To assess 
the direct effects of TNF-α on HCV and HEV replication, we employed a human hepatocyte cell line, i.e. Huh7, 
transfected with a HCV or HEV replicon luciferase as reporters. In parallel, Huh7 cells constitutively expressing 
a non-secreted firefly luciferase under control of the human phosphoglycerate kinase (PGK) promoter (LV-PGK-
Luc) were also used for normalization of nonspecific effects on luciferase signals. Both HCV and HEV replicon 
luciferase activity were significantly inhibited by treatment of cells with TNF-α (Fig. 1A,B). For instance, 100 ng/ml 
TNF-α inhibited HCV to 29 ± 2.4% (n = 5, P < 0.001), HEV to 59 ± 4.9% (n = 5, P < 0.01) at 72 hrs.
Since TNF-α has been reported to interacts with interferon signaling and ISGs are the ultimate antiviral 
effectors of the interferon cascade, we thus attempted to investigate whether TNF-α alone has any effect on 
ISG transcription. Based on the knowledge that interferon induces ISG expression via the activation of the 
ISRE motifs within the promoters of ISGs, a Huh7 cell line stably harboring a ISRE-driven luciferase reporter 
was used13. As expected, IFN-α treatment induced a strong transactivation of ISRE-driven luciferase value 
(Fig. 1C). Surprisingly, TNF-α stimulation also provoked a strong transactivation of the ISRE transcription 
elements (Fig. 1D). This interesting result prompted us to investigate the relative expression level of a panel of 
well-studied antiviral ISGs by qRT-PCR. Consistently, treatment of TNF-α provoked the induction of most 
tested ISGs, ranging from 1.7 to 11.3 fold increase (Fig. 1E). These data demonstrate that TNF-α transactivates 
the ISRE motif, resulting in the induction of ISGs, which in turn mediate the antiviral effects of TNF-α against 
HCV and HEV.
Activation of ISRE transcription by TNF-α does not require interferon production. The fact 
that TNF-α can induce ISGs inspired us to investigate the straightforward possibility that TNF-α merely trig-
gers the production of interferons. Interferon regulatory factor 1 (IRF1) was demonstrated to be important in a 
TNF-α triggered IFN-β autocrine loop in primary macrophage cells14. To dissect whether a similar mechanisms 
exist in our experiment system, we first studied the potential involvement of IRF1. Lentiviral vector was used 
to over-express IRF1 in Huh7 based ISRE-driven luciferase reporter cells and the successful over-expression of 
IRF1 was confirmed at both mRNA and protein levels (Fig. 2A,B). IRF1 over-expression significantly increased 
ISRE-regulated luciferase activity (Fig. 2C). Surprisingly, the combination of IRF1 over-expression and TNF-α 
induced a strong additive ISRE activation (Fig. 2C). Furthermore, stable IRF1 knockdown by lentiviral RNAi 
(Fig. 2D,E) had no significant effect on TNF-α induced ISRE activation (Fig. 2F). In addition, the involvement of 
another interferon regulatory factor, IRF7, was also examined via loss-of-function assay. TNF-α induced ISRE 
activation was not affected even upon the efficient IRF7 knockdown (Supplementary Figure 1A–C). These results 
suggest that TNF-α triggered ISRE activation is independent of IRF1 and IRF7.
We next investigated the effects of TNF-α on gene expression of type I interferons. As determined by 
qRT-PCR, the constitutive expression levels of IFN-α and β 1 in Huh7 cells are rather low, compared to the ref-
erence genes GAPDH and RP2 (Fig. 2G). Moreover, TNF-α treatment did not significantly increase IFN-α and 
IFN-β 1 mRNA levels (Fig. 2H). This is consistent with a previous study showing that the Huh7 cell line responds 
to interferon but does not produce interferon15. These data collectively indicate that activation of ISRE transcrip-
tion by TNF-α does not require interferon production in our model system.
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TNF-α induced ISRE activationh is independent of the JAK-STAT signaling. Classically, ISGs are 
induced by interferons via the JAK-STAT signaling. Following receptor activation by interferons, JAK1 phos-
phorylates STAT1 and Tyrosine kinase 2 (TYK2) phosphorylates STAT2. This provokes STAT1 and STAT2 
dimerization and subsequent binding to IRF9 to form the ISGF3 complex. The ISGF3 complex translocates 
into the nucleus, binds to the ISRE motif [5′ -CAGTTTCACTTTCC-3′ ] and drives the transcription of ISGs 
(Supplementary Figure 2A). To test whether activation of ISRE by TNF-α require JAK-STAT signaling, we first 
Figure 1. TNF-α activates ISG transcription and exerts antiviral activity against HCV and HEV. (A) In 
the Huh7 cell-based subgenomic HCV replicon, treatment with recombinant human TNF-α (100 ng/ml) 
inhibited HCV replication-related luciferase activity as measured at 3 different time points (n = 5). (B) Same 
as (A) for the Huh7 cell-based subgenomic HEV replicon model. (C) In the Huh7 cell-based ISRE luciferase 
reporter cells, treatment with IFN-α resulted in a dose-dependent induction of ISRE-related luciferase activity 
(n = 3 independent experiments with 2–3 replicates each). (D) Same as (C) for TNF-α . (E) Expression profile 
of 20 antiviral ISGs in Huh7 cells as measured by qRT-PCR. Most ISGs were highly up-regulated with TNF-α 
treatment (n = 5). Data presented as mean ± SD (*P < 0.05; **P < 0.01; ***P < 0.001).
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examined the role of JAKs. Strikingly, neither JAK inhibitor I (an inhibitor of JAK1, JAK2, JAK3 and TYK2) nor 
Bayer-18 (a selective TYK2 inhibitor) abrogated TNF-α induced ISRE activation (Fig. 2I and Supplementary 
Figure 2B). Consistently, TNF-α induced ISG expression was not affected by the treatment of JAK inhibitor I 
(Supplementary Figure 2D). In contrast, both IFN-α induce ISRE activation and ISG expression were largely 
blocked by JAK inhibitor I (Supplementary Figures 2C and 3A). Interestingly, the selective TYK2 inhibitor, Bayer-
18, did not significantly affect IFN-α induced ISRE activation (Supplementary Figure 2C). This is consistent with 
a previous study, showing that TYK2 plays a restricted role in IFN-α signaling16.
Figure 2. Activation of ISRE transcription by TNF-α does not require interferon production and the JAK-
STAT signaling. (A) qRT-PCR analysis of IRF1 overexpression by lentiviral vectors in the Huh7 based ISRE 
luciferase reporter cells. Compared to the control vector transduced cells, the IRF1 lentiviral vector showed 
strong IRF1 induction on RNA level. (B) Western blot analysis confirmed the successful overexpression of IRF1 
by lentiviral vectors in the Huh7 based ISRE luciferase reporter cells. (C) In the Huh7 cell-based ISRE luciferase 
reporter cells, the combination of IRF1 over-expression and TNF-α induced a strong additive ISRE activation 
as measured at 3 different time points (n = 5). (D) qRT-PCR analysis of IRF1 knockdown by lentiviral shRNA 
vectors in the Huh7 based ISRE luciferase reporter cells. Compared to the control vector transduced cells, the 
IRF1 shRNA treated clones showed strong reduction of IRF1 RNA levels. (E) Western blot analysis confirmed 
the successful knockdown of IRF1 by lentiviral shRNA vectors in the Huh7 based ISRE luciferase reporter cells. 
(F) Knockdown of IRF1 in Huh7 based ISRE luciferase reporter cells did not block TNF-α induced ISRE-related 
luciferase activation (n = 4). (G) The relative IFN-α and β 1 expression levels in Huh7 cells were determined by 
qRT-PCR. GAPDH and RP2 served as internal reference genes. (H) IFN-α and β 1 expression levels in Huh7 
cells were not up-regulated upon TNF-α treatment as measured by qRT-PCR (n = 6). (I) JAK inhibitor I (5 μ m) 
did not abrogate TNF-α induced ISRE-related luciferase activation (n = 3 independent experiments with 2–3 
replicates each). Data presented as mean ± SD (*P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant).
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Figure 3. TNF-α activates ISRE in a STAT1 independent manner. (A) Western blot analysis of total STAT1 
and phosphorylated STAT1 (Y701P) protein levels under the treatment of TNF-α (100 ng/ml), IFN-α (1000IU). 
(B) Same as (A) for the detection of total STAT2 and phosphorylated STAT2 (Y690P) protein levels under the 
treatment of TNF-α , IFN-α . (C) Confocal microscopy analysis of phosphorylated STAT1 (Y701P) localization 
in Huh7 cells treated with IFN-α or TNF-α . STAT1 was phosphorylated and translocated to the nucleus upon 
IFN-α , but not TNF-α treatment. Phosphorylated STAT1 (Y701P) antibody (green). Nuclei were visualized by 
DAPI (blue). (D) Same as (C) for the detection and localization of phosphorylated STAT2 (Y690P). (E) qRT-
PCR confirmed the successful STAT1 knockdown by lentiviral shRNA vectors in the Huh7 based ISRE luciferase 
reporter cells. (F) Western blot analysis confirmed the successful knockdown of STAT1 by lentiviral shRNA vectors 
in the Huh7 based ISRE luciferase reporter cells. (G) STAT1 knockdown had no significant influence on TNF-α 
induced ISRE-related luciferase activation as measured at 3 different time points (n = 3 independent experiments 
with 2–3 replicates each). (H) STAT1 knockdown exerts no effect on TNF-α induced ISG expression as measured 
by qRT-PCR (n = 3).
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Furthermore, to see if TNF-α treatment has any effect on STATs activation and translocation, we examined 
the phosphorylation status of STAT1 at amino acid 701 (Y701P) and STAT2 at amino acid 690 (Y690), which are 
indispensable signature of STAT1 and STAT2 activation, respectively. WB results showed TNF-α treatment had 
no effects on the phosphorylation of both STAT1 and STAT2 at indicated sites (Fig. 3A,B). Confocal microscopy 
analysis also confirmed that IFN-α induced the activation and nuclear translocation of STAT1 and STAT2 via the 
phosphorylation at indicated sites, while TNF-α had no effects (Fig. 3C,D). To further exclude a role of STAT1 in 
TNF-α induced ISRE activation, lentiviral RNAi was used to knockdown STAT1. The stable STAT1 knockdown 
(Fig. 3E,F) had no effect on both TNF-α induced ISRE activation and ISG expression (Fig. 3G,H). Collectively, 
TNF-α triggered ISRE activation is totally independent of STAT1.
In addition, the role of IRF9 was also verified, which is a key downstream element of interferon pathway. IRF9 
was up-regulated and translocated into cell nucleus upon IFN-α stimulation, whereas TNF-α stimulation did not 
induce the translocation of IRF9 into cell nucleus (Supplementary Figure 3B). These results collectively demon-
strate that TNF-α induced ISRE activation is independent of the JAK-STAT signaling.
TNF-α activates ISRE via TNF receptor 1. TNF receptor (TNFR) is the important upstream component 
in TNF-α induced signaling transduction. TNF acts through two receptors, TNFR1 and TNFR2. TNFR1 is the 
major signaling receptor for TNF-α and is expressed by all human tissues, while TNFR2 is mostly expressed in 
immune cells and mediates limited biological responses17. In light of the fact that TNF-α is capable of activating 
ISG transcription, we sought to determine whether this action of TNF-α was mediated via TNFR. For this, the 
ISRE reporter cell line was transduced with integrating lentiviral RNAi vectors to silence TNFR1, resulting in a 
profound down-regulation of TNFR1 expression (Fig. 4A). As expected, IFN-α induced ISRE activation was not 
influenced (Fig. 4B), but TNF-α induced ISRE luciferase activity was largely abrogated in TNFR1 knockdown 
cells when compared to control cells (Fig. 4C). Consistently, the induction of ISGs by TNF-α was also blocked by 
TNFR1 knockdown ( Supplementary Figure 4A).
To further confirm these results, the clinically widely used drug for rheumatoid arthritis patients and Crohn′ s 
disease, Humira (adalimumab), was used. Humira binds specifically to TNF-α and blocks its interaction with 
TNF receptors. As expected, Humira effectively blocks TNF-α induced activation of NF-κ B luciferase activity 
(Fig. 5A), NF-κ B activity being a well-known downstream effect of TNF-α receptor ligation. Importantly, both 
Figure 4. TNF-α activates ISRE via TNF receptor I. (A) qRT-PCR analysis of TNFR1 knockdown by 
lentiviral shRNA vectors in the Huh7 based ISRE luciferase reporter cells. Compared to the control vector 
transduced cells, the two shRNA treated clones (sh-02 and sh-03) showed strong reduction of TNFR1 RNA 
levels. (B) TNFR1 knockdown had no significant influence on IFN-α induced ISRE-related luciferase activation 
as measured at 3 different time points (n = 3 independent experiments with 2–3 replicates each). (C) TNFR1 
knockdown blocked TNF-α induced ISRE-related luciferase activation as measured at 3 different time points 
(n = 3 independent experiments with 2–3 replicates each).
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Figure 5. Both TNF-α induced ISG expression and antiviral activity against HCV and HEV were abrogated 
by its inhibitor Humira. (A) In the Huh7 cell-based NF-κ B luciferase reporter cells, the TNF-α inhibitor, 
Humira, abrogated TNF-α induced NF-κ B-related luciferase activation as measured at 3 different time points 
(n = 3 independent experiments with 2–3 replicates each). (B) Same as (A) for the Huh7 cell-based ISRE luciferase 
reporter cells. (C) In Huh7 cells, the TNF-α inhibitor, Humira, abrogated TNF-α induced ISG expression as 
measured by qRT-PCR (n = 4). (D) In the Huh7 cell-based subgenomic HCV replicon, Humira abrogated the 
TNF-α induced anti-HCV effect as measured at 3 different time points (n = 3 independent experiments with 
2–3 replicates each). (E) Same as (D) for Huh7 cell-based subgenomic HEV replicon. (F) TNF-α levels in serum 
samples collected from anti-TNF-α treatment naive Crohn’s disease patients were measured by ELISA kit (left). 
Serum samples with higher TNF-α levels showed stronger ISRE-related luciferase activity compared with control 
serum as measured at 3 different time points. Data presented as mean ± SD. (*P < 0.05; **P < 0.01; ***P < 0.001; 
ns, not significant).
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TNF-α induced ISRE luciferase activity and ISG expression were also abrogated by Humira treatment (Fig. 5B,C). 
This effect was not limited to Huh7 cells, but also observed in a human lung cell line, A549 (Supplementary 
Figure 4B). More relevantly, Humira totally abolished TNF-α mediated antiviral effect against HCV and HEV 
(Fig. 5D,E), providing a possible explanation for the high risk of infection in patients treated with TNF-α inhibi-
tors. Next, we collected serum samples from anti-TNF-α treatment naive Crohn’s disease patients and measured 
the serum TNF-α levels by ELISA. 3 serum samples with high TNF-α levels were selected to treat Huh7 based 
Figure 6. TNF-α mediates the induction of ISRE by activation of the NF-κB signaling. (A) Confocal 
microscopy analysis of RelA induction and localization in Huh7 cells treated with TNF-α . RelA was induced 
and translocated to the nucleus upon TNF-α treatment. RelA antibody (green). Nuclei were visualized by DAPI 
(blue). (B) Western blot analysis confirmed the successful knockdown of RelA by lentiviral shRNA vectors in 
the Huh7 based ISRE luciferase reporter cells. (C) RelA knockdown largely blocked TNF-α induced ISRE-
related luciferase activation as measured at 3 different time points (n = 3 independent experiments with 2–3 
replicates each). (D) RelA knockdown largely blocked TNF-α induced ISG expression as measured by qRT-PCR 
(n = 4). (E) RelA knockdown has no significant influence on IFN-α induced ISRE-related luciferase activation 
as measured at 3 different time points (n = 3 independent experiments with 2–3 replicates each). Data presented 
as mean ± SD (*P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant).
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Figure 7. The NF-κB complex directly binds to ISRE and drives its transcriptional activity. (A) NF-κ B and 
ISRE sequence specific binding regions. Their consensus nucleotides are labeled in red color, and the consensus 
region is enclosed by the rectangular box. (B) Heatmaps display the normalized ChIP-seq reads representing 
the binding intensity of STAT1 and RelA. Displayed are 8 kb regions centered on the summits of significant 
STAT1 and/or RelA binding sites. The heatmap are clustered for the STAT1 and RelA binding signal based on 
the central 0.5 kb of the heatmap. left) Heatmaps of all significant STAT1 and RelA binding sites (n = 13367). 
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ISRE-driven luciferase reporter cells (Fig. 5F). Consistently, all 3 serum samples exerted higher ISRE activity 
compared to control serum sample (Fig. 5F, right). Furthermore, Humira decreased the serum induced ISRE 
activity (Supplementary Figure 4C). More interestingly, serum samples with higher TNF-α levels inhibited 
HCV-related luciferase activity compared to control serum sample (Supplementary Figure 4D). Collectively, these 
results demonstrate that TNF-α acts via its receptor to activate ISG transcription and exerts antiviral activity, 
which can be blocked by clinically used TNF-α inhibitor.
TNF-α mediates the activation of ISRE through NF-κB signaling. Activation of NF-κ B signal-
ing is one of the most important canonical responses to the stimulation of TNF-α . Following TNF receptor 
activation by TNF-α , inhibitor of kappa B (IkB) proteins undergo phosphorylation dependent ubiquitination 
and degradation, resulting in the activation and translocation of NF-κ B dimers into the cell nucleus. In the cell 
nucleus, NF-κ B dimers bind to the specific NF-κ B motifs, [5′ -GGGAA/CTTTCC-3′ ], within the promoter 
regions driving the expression of NF-κ B target genes (Supplementary Figure 5A). Because some studies have 
reported that TNF-α can also increase the transcriptional activity of activator protein-1 (AP-1) in some specific 
cell types18,19, we thus created Huh7 based stable NF-κ B or AP-1 driven luciferase reporter cell lines, respec-
tively. As shown in Supplementary Figure 5B, stimulation with TNF-α led to strong activation of NF-κ B lucif-
erase activity, but no significant effect on AP-1 activity. Therefore, we only focused on NF-κ B signaling for the 
following investigation.
The NF-κ B complex is the endpoint of its signal transduction, which comprises the heterodimeric RelA 
(P65)-P50 complex. Indeed, unstimulated cells display little nuclear RelA, but the RelA protein level in the 
cell nucleus was substantially elevated following TNF-α stimulation (Fig. 6A). Thus, to dissect the role of the 
RelA (P65) - P50 complex in TNF-α induced ISRE activation, the Huh7 ISRE reporter cell line was trans-
duced with integrating lentiviral RNAi vectors to silence RelA (P65), resulting in profound down-regulation of 
RelA expression (Fig. 6B). Consistently, TNF-α induced ISRE luciferase activity and ISG expression was largely 
demolished in RelA knockdown cells when compared with control cells (Fig. 6C,D). On the contrary, IFN-α 
induced ISRE activation was not affected (Fig. 6E). Thus, NF-κ B signaling appears to be essential for TNF-α 
mediated ISRE activation.
The NF-κB complex directly binds to ISRE and drives its transcriptional activity. Upon TNF-α 
stimulation and signaling activation, the transcription factor complex, NF-κ B, can bind to a sequence specific 
motif [5′ -GGGAA/CTTTCC-3′ ] to promote target gene transcription13,20–22. The puzzling role of NF-κ B in the 
transactivation of ISRE led us to perform an in silico analysis comparing the ISRE motif and the NF-κ B DNA 
binding site. Surprisingly, we identified a partial consensus sequence region in common within these two motifs 
(Fig. 7A). We thus hypothesized that NF-κ B might bind to this consensus sequence within the ISRE motif to 
drive transcription of corresponding ISGs. To test this hypothesis, we retrieved genome wide RelA and STAT1 
(positive control) ChIP-seq data from the ENCODE ChIP-seq Experiment Matrix database. ChIP-seq datasets 
were processed and analyzed. Confirming our hypothesis, we found that RelA showed a similar genome-wide 
binding pattern with STAT1. For a large cohort of genes, RelA overlapped with STAT1 in their gene binding site 
(Fig. 7B, left). To be more specifically, we further analyzed the RelA and STAT1 binding sites that were within 1 kb 
of a transcription start site. This region is frequently located at the site of the promoter. Consistently, RelA still 
overlaps with STAT1 in the specific binding sites near gene transcription start sites. Since most genes bound and 
regulated by STAT1 are ISGs, this indicates that RelA also possesses the ability to bind and regulate a large cohort 
of ISGs. Then we analyzed RelA binding on a list of well-established antiviral ISGs. Convincingly, RelA shows 
strong and specific binding on the promoters of indicated ISGs, while the rabbit-IgG (negative control) shows 
no significant binding (Fig. 7C). To further confirm that NF-κ B binds to the consensus sequence within the 
ISRE motif to drive corresponding ISG transcription, we mutated the consensus nucleotide sequence within the 
ISRE motif based on the lentiviral transcriptional reporter vector expressing the firefly luciferase gene driven by 
multiple ISREs. In theory, RelA will not be able to bind to this mutant ISRE sequence (Supplementary Figure 6). 
Huh7 cells were transduced with this vector to create a stable reporter cell line. As expected, TNF-α failed to 
activate this mutated ISRE (Fig. 7D). Hence, NF-κ B can directly bind to the ISRE motif and activate its tran-
scriptional activity.
TNF-α cooperates with IFN-α in ISG induction and antiviral action. Because of the distinct signal-
ing cascades that finally converge the transcription of antiviral ISGs by TNF-α and interferons, we further inves-
tigated the combinatory effects of TNF-α with IFN-α on ISG induction and antiviral action. Thus, we quantified 
the expression levels of a list of well-known antiviral ISGs in the Huh7 cell line with treatment of TNF-α , IFN-α 
or a combination thereof. Both TNF-α and IFN-α can induce significant up-regulation of tested ISGs, and their 
combination resulted in a strong additive induction of ISGs (Fig. 8A).
right) Heatmap of all significant STAT1 and RelA binding sites that are within 1 kb of a transcription start site 
(n = 4545). (C) Binding of RelA to the promoters of the indicated ISGs. Sequence reads from anti-RelA ChIP-
seq or rabbit-IgG-control were plotted relative to chromosomal position. Genome location of corresponding 
ISGs is shown beneath the track signaling. RelA shows strong and specific binding on the promoters of 
indicated ISGs, while the rabbit-IgG, serving as negative control, shows no significant binding. (D) In the Huh7 
cell-based mutant ISRE luciferase reporter cells, TNF-α did not induce mutant ISRE related luciferase activation 
as measured at 3 different time points (n = 3 independent experiments with 2–3 replicates each). Data presented 
as mean SD (*P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant).
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Consistent with a previous publication23, our results of ISG antiviral assay (Supplementary Figure 7) again 
highlight the important antiviral role of ISGs. Thus, the cooperation in ISG induction prompted us to test whether 
an additive antiviral effect can be achieved with the combination of TNF-α and IFN-α . Hence, we employed 
Figure 8. TNF-α cooperates with IFN-α in ISG induction and antiviral action. (A) In the Huh7 cells, the 
combination of TNF-α and IFN-α induced a strong additive ISG expression compared with treatment of 
either TNF-α or IFN-α alone as measured by qRT-PCR (n = 6). (B) In the Huh7 cell-based subgenomic HCV 
replicon model, the combination of TNF-α and IFN-α induced a strong additive anti-HCV effect compared 
with treatment of either TNF-α or IFN-α alone as measured at 3 different time (n = 3 independent experiments 
with 2–3 replicates each). (C) Same as (B) for the Huh7 cell-based subgenomic HEV replicon model.
www.nature.com/scientificreports/
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the Huh7 cell line based HCV or HEV replicon luciferase reporter as the cell models for the test. As shown in 
Fig. 8B,C, the combination of TNF-α and IFN-α resulted in additive antiviral effects in both HCV and HEV 
replicon models. Thus, TNF-α cooperates with IFN-α in ISG induction, explaining their additive antiviral effects 
against HCV and HEV as we observed.
Discussion
TNF-α is a cytokine within the TNF superfamily, which acts as a central mediator of inflammation and 
immune regulations. Although TNF-α was first noted for its role in the killing of tumor cells24, it has plei-
otropic functions that include the inflammatory response and host resistance to pathogens. Indeed, numer-
ous studies have demonstrated the importance of TNF-α  in protection against pathogens, including 
Mycobacterium tuberculosis, Cryptococcus neoformans, vesicular stomatitis virus, encephalomyocarditis virus, 
herpes simplex virus, influenza virus and hepatitis B virus25–29. Disordered TNF-α regulation may have a sig-
nificant negative role in inflammation and pathogenesis. Based on this, TNF-α antagonists have been proven 
to be highly effective in the treatment of certain inflammatory diseases, such as rheumatoid arthritis30, pso-
riatic arthritis31, juvenile rheumatoid arthritis32, and Crohn’s disease33. Several TNF-α inhibitors have been 
approved for the treatment of these inflammatory illnesses by the US Food and Drug Administration (FDA). 
Contradictory, many studies have demonstrated an increased risk of opportunistic infections and difficulty in 
clearing infections once they develop in patients treated with TNF-α inhibitors, such as HBV or HCV infec-
tion34–36. Our experimental results showing that clinically used anti-TNF-α inhibitors can totally abrogate the 
antiviral activity of TNF-α appear to support those clinical observations and highlight the primary role of 
TNF-α in host defense against infections.
As a first line defense, TNF-α and type I interferons are induced by microbial stimuli and mediate innate 
immune responses. Despite the fact that cells at sites of infection are continuously exposed to both cytokines, 
the interactions between TNF-α and interferons remain under investigated37. Although previous studies have 
reported that TNF-α interacts with antiviral interferon signaling and regulates ISG expression in the setting of 
different virus infections8–10, the molecular mechanisms behind these interactions have not been delineated. 
In this study, we demonstrated that the activation of NF-κ B signaling by TNF-α was able to directly transac-
tivate the ISRE motif, resulting in the induction of antiviral ISGs. This whole process is independent of IFN 
production and the canonical JAK-STAT cascade, but relies on TNF-α induced NF-κ B activity. NF-κ B is a 
homo- or heterodimeric complex formed by the Rel-like domain-containing proteins: RelA (P65), RelB, c-Rel, 
P50 and P52 and the heterodimeric RelA (P65)-P50 complex appear to be the most abundant one. The dimers 
bind to the sequence specific NF-κ B response element in the promoter region of their target genes to regulate 
transcription. To our surprise, in silico analysis discovered a consensus nucleotide sequence shared by the 
ISRE motif and NF-κ B DNA binding site. ChIP-seq data analysis reveals RelA (P65) can directly bind to the 
promoter region of a large cohort of ISGs. Our loss-of-function and mutagenesis assay further confirmed that 
NF-κ B could directly drive ISRE-controlled gene transcription. Since NF-κ B is also the key downstream effec-
tor of most Toll-like receptors (TLR), this novel mechanism may also partially explain the antiviral activities 
of TLR agonists in clinic, such as the TLR7 agonists, which are being therapeutically targeted and explored for 
HCV treatment in clinic trial38.
More excitingly, TNF-α not only activates antiviral ISGs transcription, but also cooperates with IFN-α , 
explaining the additive antiviral outcome of their combination. This highlights the important facts that differ-
ent cytokines orchestrate innate immune responses by activating signaling cascades to protect against infection 
efficiently.
In conclusion, we revealed a novel antiviral mechanism of TNF-α . TNF-α ,via the activation of NF-κ B cas-
cade, can drive the transcription of antiviral ISGs through direct binding of ISREs. This antiviral mechanism 
may provide clues for tackling the high rise of infections caused by TNF-α inhibitor treatment in patients. More 
interestingly, TNF-α also acts cooperatively with IFN-α in antiviral ISGs induction to exert additive antiviral 
effects. These findings not only provide new clues for understanding virus-host interactions but also assign a 
novel function of the canonical NF-κ B pathway.
Materials and Methods
The HCV subgenomic replicon comprised Huh7 cells containing a subgenomic HCV bicistronic replicon 
(1389/NS3-3 V/LucUbiNeo-ET) linked to the firefly luciferase reporter gene were maintained with 250 μ g/
ml G418 (Sigma, Zwijndrecht, the Netherlands). The HEV subgenomic model was based on Huh7 cells con-
taining the subgenomic HEV sequence (Kernow-C1 p6/luc) coupled to a Gaussia luciferase reporter gene. 
Lentiviral pLKO knockdown vectors (Sigma–Aldrich) targeting IRF1, TNFR1, RelA were obtained from the 
Erasmus Biomics Center and produced in HEK293T cells as previously described39. The use of serum samples 
from IBD patients was approved by the Medical Ethical Committee of the Erasmus Medical Center (Medisch 
Ethische Toetsings Commissie Erasmus MC), and the informed consent was obtained from all subjects. All 
methods were carried out in accordance with the approved guidelines. For more details, see Supplementary 
Information.
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